📌A recent retrospective cohort study of 1128 patients in hospital with #COVID19 suggests that patients who received an #ACEinhibitor or ARB while in the hospital had improved outcomes over those who received neither medication https://t.co/OkNMluVz7g @CMAJ
RT @RevistaMFSamfyc: Inhibidores del sistema renina-angiotensina-aldosterona y COVID-19 https://t.co/M8HLwaNfAR PMID 32332039
Inhibidores del sistema renina-angiotensina-aldosterona y COVID-19 https://t.co/M8HLwaNfAR PMID 32332039
Great commentary on prescribing RAAS inhibition during #COVID19 pandemic @CMAJ @kieranlquinn @FralickMike @JonZipursky @NathanStall
RT @ADetsky: Very thoughtful essay on this important topic. Don’t get mad, get data !
RT @ADetsky: Very thoughtful essay on this important topic. Don’t get mad, get data !
Very thoughtful essay on this important topic. Don’t get mad, get data !
RT @kieranlquinn: Excited to share our commentary on prescribing guidance for RAAS inhibitors and #COVID19 published today in @CMAJ @Nath…
RT @JonZipursky: Our latest in @CMAJ on RAAS inhibitors in #COVID19 @kieranlquinn @FralickMike @NathanStall @Sunnybrook @ClinPharm_UofT @…
RT @JonZipursky: Our latest in @CMAJ on RAAS inhibitors in #COVID19 @kieranlquinn @FralickMike @NathanStall @Sunnybrook @ClinPharm_UofT @…
RT @kieranlquinn: Excited to share our commentary on prescribing guidance for RAAS inhibitors and #COVID19 published today in @CMAJ @Nath…
Our latest in @CMAJ on RAAS inhibitors in #COVID19 @kieranlquinn @FralickMike @NathanStall @Sunnybrook @ClinPharm_UofT @DavidJuurlink @UofT_DoM @SinaiHealth
RT @kieranlquinn: Excited to share our commentary on prescribing guidance for RAAS inhibitors and #COVID19 published today in @CMAJ @Nath…
RT @kieranlquinn: Excited to share our commentary on prescribing guidance for RAAS inhibitors and #COVID19 published today in @CMAJ @Nath…
Don't stop high blood pressure medications because of #COVID19: Abrupt withdrawal or substitution of RAAS inhibitors may lead to worse outcomes. https://t.co/pZ21Wq97mX https://t.co/yZxn1xQWZK
RT @kieranlquinn: Excited to share our commentary on prescribing guidance for RAAS inhibitors and #COVID19 published today in @CMAJ @Nath…
RT @kieranlquinn: Excited to share our commentary on prescribing guidance for RAAS inhibitors and #COVID19 published today in @CMAJ @Nath…
RT @kieranlquinn: Excited to share our commentary on prescribing guidance for RAAS inhibitors and #COVID19 published today in @CMAJ @Nath…
RT @kieranlquinn: Excited to share our commentary on prescribing guidance for RAAS inhibitors and #COVID19 published today in @CMAJ @Nath…
@UofTDoMChair @UofT_DoM @GIMtoronto @HTNCanada @DiabetesCanada @SCC_CCS @SinaiHealth
RT @kieranlquinn: Excited to share our commentary on prescribing guidance for RAAS inhibitors and #COVID19 published today in @CMAJ @Nath…
Excited to share our commentary on prescribing guidance for RAAS inhibitors and #COVID19 published today in @CMAJ @NathanStall @FralickMike @JonZipursky @jayudell @ADetsky @DrJeffKwong @BogochIsaac https://t.co/aAjWnrRfyG
Renin–angiotensin–aldosterone system inhibitors and COVID-19 | CMAJ https://t.co/rbAXmnXsfI